Contributions
Abstract: EP1579
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Introduction: Biomarkers that could be used in early diagnosis of multiple sclerosis (MS), segregation of disease subtypes and discrimination of the aggressive disease course from the benign one are urgently needed. Circulating microRNAs (miRNA) have great biomarker potential, due to their exceptional stability in body fluids and relative ease of collection and quantification. Aberrant miRNA expression levels were previously reported in multiple MS studies, with less attention paid to circulating miRNAs, especially to their longitudinal stability.
Previously we reported miR-191-5p and miR-24-3p to be overexpressed in relapsing-remitting (RRMS) and primary progressive (PPMS) MS, while miR-128-3p showed tendency towards the predominant expression in PPMS.
Objectives: Study association of miR-24-3p, miR-191-5p, miR-128-3p and miR-223-3p to disability accumulation and disease activity over the 4-year follow-up cohort, as well as to evaluate their correlations to MRI findings.
Aims: Assess the stability of specific miRNA expression in longitudinal study to highlight its promising biomarker potential.
Methods: The expression of miR-24-3p, miR-191-5p, miR-128-3p and miR-223-3p were analyzed in sera samples of 32 RRMS, 15 SPMS, 15 PPMS and 19 CIS patients at the baseline, 2 and 4-years after the study enrollment, as well as in 30 HC.
Results: We have detected longitudinal variability in circulating miRNA expression levels, in RRMS, PPMS, SPMS and CIS patients. These miRNAs were stable, when studied in HC.
Conclusions: Our results indicate an abnormal expression and longitudinal variability of microRNAs in MS. While our MRI result are under analysis now, we believe that our findings will be of interest to ECTRIMS conference participants.
Disclosure: Julia Vistbakka: nothing to disclose, Irina Elovaara: nothing to disclose, Terho Lehtimäki: nothing to disclose, Marja-Liisa Sumelahti: nothing to disclose, Sanna Hagman: nothing to disclose
Abstract: EP1579
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Introduction: Biomarkers that could be used in early diagnosis of multiple sclerosis (MS), segregation of disease subtypes and discrimination of the aggressive disease course from the benign one are urgently needed. Circulating microRNAs (miRNA) have great biomarker potential, due to their exceptional stability in body fluids and relative ease of collection and quantification. Aberrant miRNA expression levels were previously reported in multiple MS studies, with less attention paid to circulating miRNAs, especially to their longitudinal stability.
Previously we reported miR-191-5p and miR-24-3p to be overexpressed in relapsing-remitting (RRMS) and primary progressive (PPMS) MS, while miR-128-3p showed tendency towards the predominant expression in PPMS.
Objectives: Study association of miR-24-3p, miR-191-5p, miR-128-3p and miR-223-3p to disability accumulation and disease activity over the 4-year follow-up cohort, as well as to evaluate their correlations to MRI findings.
Aims: Assess the stability of specific miRNA expression in longitudinal study to highlight its promising biomarker potential.
Methods: The expression of miR-24-3p, miR-191-5p, miR-128-3p and miR-223-3p were analyzed in sera samples of 32 RRMS, 15 SPMS, 15 PPMS and 19 CIS patients at the baseline, 2 and 4-years after the study enrollment, as well as in 30 HC.
Results: We have detected longitudinal variability in circulating miRNA expression levels, in RRMS, PPMS, SPMS and CIS patients. These miRNAs were stable, when studied in HC.
Conclusions: Our results indicate an abnormal expression and longitudinal variability of microRNAs in MS. While our MRI result are under analysis now, we believe that our findings will be of interest to ECTRIMS conference participants.
Disclosure: Julia Vistbakka: nothing to disclose, Irina Elovaara: nothing to disclose, Terho Lehtimäki: nothing to disclose, Marja-Liisa Sumelahti: nothing to disclose, Sanna Hagman: nothing to disclose